Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2592 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorized share capital and provides details on issued shares and treasury shares. The report indicates that there were no changes in the number of issued or treasury shares during the month. Additionally, it confirms compliance with public float requirements as per exchange rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cloudbreak Pharma, Inc. on 6ix
Earlier from Cloudbreak Pharma
- Formation of an independent Special committee; delay in publication and despatch of 2026 interim report; and continued suspension of trading
- List of directors and their roles and functions
- Appointment of independent non-executive directors and continued suspension of trading
- Business updates and supplemental announcement in relation to 2025 annual report
- Suspension of trading
Follow Cloudbreak Pharma into a list and get an email when it puts out news.
Follow Cloudbreak Pharma